Skip to main content

Abstract

Challenges can arise in the management of chronically-transfused patients. Solve it!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:303.

    Article  Google Scholar 

  2. Hayes MM, Vedamurthy A, George G, Dweik R, Klings ES, Machado RF, et al. Pulmonary hypertension in sickle cell disease. Ann Am Thorac Soc. 2014;11(9):1488–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusion in children with abnormal results of transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.

    Article  CAS  PubMed  Google Scholar 

  4. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.

    Article  CAS  PubMed  Google Scholar 

  5. Randolph TR. Hemoglobinopathies (structural defects in hemoglobin). In: Keohane EM, Otto CN, Walenga JM, editors. Rodak’s hematology. Clinical principles and applications. 6th ed. Amsterdam: Elsevier; 2020. p. 406–8.

    Google Scholar 

  6. Biller E, Zhao Y, Berg M, Boggio L, Capocelli KE, Fang DC, et al. Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. Transfusion. 2018;58(8):1965–72.

    Article  PubMed  Google Scholar 

  7. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–69.

    Article  CAS  PubMed  Google Scholar 

  8. Stussi G, Buser A, Holbro A. Red blood cells: exchange, transfuse, or deplete. Transfus Med Hemother. 2019;46(6):407–16.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ziemba Y, Xu C, Fomani KM, Nandi V, Yuan T, Rehmani S, et al. Safety and benefits of automated red cell depletion-exchange compared to standard exchange in patients with sickle cell disease undergoing chronic transfusion. Transfusion. 2021;61(2):526–36.

    Article  CAS  PubMed  Google Scholar 

  10. EXJADE® prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp. April 2011.

    Google Scholar 

  11. Desferal® prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp. July 2019.

    Google Scholar 

  12. HYDREA® prescribing information. Princeton, NJ: Bristol-Myers Squibb Co. March 2016.

    Google Scholar 

  13. Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30(2):91–6.

    Article  PubMed  Google Scholar 

  14. SIKLOS® prescribing information. Bryn Mawr, PA: Medunik USA. December 2017.

    Google Scholar 

  15. Ware RE, Helms RW, SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10,019):661–70.

    Article  CAS  PubMed  Google Scholar 

  17. ENDARI™ prescribing information. Torrence, CA: Emmaus Medical. July 2017.

    Google Scholar 

  18. OXBRYTA® prescribing information. South San Francisco, CA: Global Blood Therapeutics. January 2021.

    Google Scholar 

  19. Rutherford-Parker NJ, Campbell ST, Colby JM, Shajani-Yi Z. Voxelotor treatment interferes with quantitative and qualitative hemoglobin variant analysis in multiple sickle cell disease genotypes. Am J Clin Pathol. 2020;154(5):627–34.

    Article  CAS  PubMed  Google Scholar 

  20. ADAKVEO® prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp. July 2021.

    Google Scholar 

  21. Ribeil J-A, Bey-Abina SH, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–55.

    Article  CAS  PubMed  Google Scholar 

  22. King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–94.

    Article  CAS  PubMed  Google Scholar 

  23. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Further Reading

  • Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.

    Article  CAS  PubMed  Google Scholar 

  • Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusion in children with abnormal results of transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark T. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Heavy Metal. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_74

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14638-1_74

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14637-4

  • Online ISBN: 978-3-031-14638-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics